Holly B. Kordasiewicz net worth and biography

Holly Kordasiewicz Biography and Net Worth

Executive Vice President, Chief Development Officer of Ionis Pharmaceuticals

Dr. Holly Kordasiewicz is the executive vice president and chief development officer at Ionis Pharmaceuticals, where she is responsible for preclinical development, clinical development, regulatory affairs and drug safety for Ionis’ antisense medicines.

Since joining Ionis, Dr. Kordasiewicz has played a central role in building and expanding the neurology organization. She led the preclinical research for QALSODY® (tofersen), an antisense oligonucleotide (ASO) treatment for a rare, genetic form of amyotrophic lateral sclerosis (ALS). Under her direction, the neurology team developed a robust pipeline of RNA-targeted therapies aimed at treating a range of serious neurological diseases, including ALS, Alzheimer’s disease, and multiple rare neurological diseases. In her tenure at Ionis, she has successfully transitioned several medicines from research into development.

Dr. Kordasiewicz earned her Ph.D. in neuroscience from the University of Minnesota, where she studied molecular mechanisms underlying neurodegeneration. She then completed her postdoctoral training in the laboratory of Dr. Don Cleveland at the University of California, San Diego, where she contributed to early preclinical validation efforts for ASO therapies.

What is Holly B. Kordasiewicz's net worth?: The estimated net worth of Holly B. Kordasiewicz is at least $1.24 million as of January 16th, 2026. Dr. Kordasiewicz owns 14,718 shares of Ionis Pharmaceuticals stock worth more than $1,244,996 as of February 4th. This net worth approximation does not reflect any other investments that Dr. Kordasiewicz may own. Learn More about Holly B. Kordasiewicz's net worth.
How do I contact Holly B. Kordasiewicz?: The corporate mailing address for Dr. Kordasiewicz and other Ionis Pharmaceuticals executives is 2855 GAZELLE COURT, CARLSBAD CA, 92010. Ionis Pharmaceuticals can also be reached via phone at (760) 931-9200 and via email at [email protected]. Learn More on Holly B. Kordasiewicz's contact information.
Has Holly B. Kordasiewicz been buying or selling shares of Ionis Pharmaceuticals?: During the last ninety days, Holly B. Kordasiewicz has sold $313,308.06 of Ionis Pharmaceuticals stock. Most recently, Holly B. Kordasiewicz sold 4,141 shares of the business's stock in a transaction on Friday, January 16th. The shares were sold at an average price of $75.66, for a transaction totalling $313,308.06. Following the completion of the sale, the executive vice president now directly owns 14,718 shares of the company's stock, valued at $1,113,563.88. Learn More on Holly B. Kordasiewicz's trading history.
Who are Ionis Pharmaceuticals' active insiders?: Ionis Pharmaceuticals' insider roster includes Joseph Baroldi (EVP & Chief Business Officer), C. Bennett (EVP), Spencer Berthelsen (Director), Brian Birchler (EVP), Onaiza Cadoret-Manier (EVP), Breaux Castleman (Director), Stanley Crooke (Chairman), Shannon Devers (Executive Vice President, Chief Human Resources Officer), Allene Diaz (Director), Richard Geary (EVP), Michael Hayden (Director), Elizabeth Hougen (CFO), Kyle Jenne (Executive Vice President, Chief Global Product Strategy Officer), Joseph Klein, III (Director), Holly Kordasiewicz (Executive Vice President, Chief Development Officer), Brett Monia (CEO), Frederick Muto (Director), Patrick O'Neil (EVP), B. Parshall, Esq. (Director), Eugene Schneider (EVP), Eric Swayze (EVP), and Joseph Wender (Director). Learn More on Ionis Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Ionis Pharmaceuticals?: During the last year, Ionis Pharmaceuticals insiders bought shares 1 times. They purchased a total of 15,000 shares worth more than $477,900.00. During the last year, insiders at the sold shares 76 times. They sold a total of 1,346,160 shares worth more than $89,921,385.44. The most recent insider tranaction occured on January, 30th when EVP Eric Swayze sold 6,179 shares worth more than $512,424.47. Insiders at Ionis Pharmaceuticals own 2.7% of the company. Learn More about insider trades at Ionis Pharmaceuticals.
Information on this page was last updated on 1/30/2026.

Holly B. Kordasiewicz Insider Trading History at Ionis Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
1/16/2026	Sell	4,141	$75.66	$313,308.06	14,718

Holly B. Kordasiewicz Buying and Selling Activity at Ionis Pharmaceuticals

Ionis Pharmaceuticals Company Overview

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.

Today's Range

Now: $84.59

$83.00

$85.45

50 Day Range

MA: $80.42

$76.33

$84.59

2 Week Range

Now: $84.59

$23.95

$86.15

Volume

1,453,463 shs

Average Volume

2,349,598 shs

Market Capitalization

$13.70 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.29